Posted by Michael Wonder on 07 Nov 2025
Mark Cuban is trying to shake up biosimilar pricing with a version of J&J’s best selling Stelara drug
6 November 2025 - By selling at a low price, Cuban hopes to convince health plans, employers to embrace his approach
In its latest bid to shake up the prescription drug market, the Mark Cuban Cost Plus Drug Company has reached a deal to sell a cheap, biosimilar version of Stelara, a widely prescribed treatment for chronic inflammatory and auto-immune conditions.
The company plans to sell the lower cost medication for $345 every three months, or $1,380/year, for a 90 mg dose, before shipping costs. This is significantly below the list price for the brand name drug sold by Johnson & Johnson, which can vary depending on patient weight and the specific illness being treated.
